Navigation Links
Med Discovery and Laborium Biopharma Sign a Bioprocess Development Partnership Agreement
Date:11/19/2008

Med Discovery S.A., a Swiss biotech firm and Laborium Biopharma, a subsidiary of Validapro Biosciences Inc. have signed a partnership agreement for the development and optimization of protein bioprocess production and scale-up.

Laval, Quebec (PRWEB) November 19, 2008 -- Med Discovery S.A., a Swiss biotech firm and Laborium Biopharma, a subsidiary of Validapro Biosciences Inc. have signed a partnership agreement for the development and optimization of protein bioprocess production and scale-up.

The first project pursued by the partners is Med Discovery's kallikrein inhibitor MDPK67b, a recombinant therapeutic protein which regulates different biological pathways involved in prostate cancer. The activity of MDPK67b has been validated in animal models of human prostate tumors.

Under the terms of this agreement, Laborium Biopharma will complete the bacterial production process and scale-up, and produce cGMP clinical material required to perform Phase I/IIa clinical trials.

Dr. David Deperthes, President and CEO at Med Discovery, commented: "This ambitious project requires a high level of technical expertise and top quality processes that meet the strictest regulatory standards. This collaboration is crucial, as it provides the platform for the development of our early-phase projects. We believe that Laborium Biopharma represents the ideal partner to help us successfully complete this critical phase of our MDPK67b development program."

Luc Dubois, President of Laborium Biopharma, said: "We are very pleased to collaborate with Med Discovery, a bright and innovative company and are proud of their trust in our capabilities. We will work diligently to help Med Discovery meet the strategic objective of testing its promising therapeutic protein in humans before the end of 2009."

Med Discovery S.A. is a private biopharmaceutical company headquartered in Geneva, Switzerland focusing on treatments for uro-genital cancers. The company is dedicated to the discovery and the development of highly specific protein drugs based on the optimization of natural proteins involved in the regulation of biological pathways. The company is leveraging a strong in-house expertise combined with an international network in clinical urology.

Laborium Biopharma is a private corporation based in the Biotechnology Research Institute of the National Research Council Canada in Montreal, Quebec. This new company is dedicated to the development and optimization of bio-production processes and the cGMP manufacturing of clinical batches of high-potency products.

###

Read the full story at http://www.prweb.com/releases/2008/11/prweb1641134.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Telik Announces New TRAP Drug Discovery Agreement
2. MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery
3. TIBCO Speeds Drug Discovery for Chemists
4. Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts
5. deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer
6. Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
7. The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
8. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
9. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
10. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
11. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Med Discovery and Laborium Biopharma Sign a Bioprocess Development Partnership Agreement
(Date:2/28/2017)... and REYKJAVIK, Iceland , Feb. 28, ... group company and the contract genomics organization enabling precision ... Hannes Smarason has been appointed as the company,s chief executive ... and Alex Fowkes have been named chief ... "WuXi NextCODE is executing on its vision to enable anyone ...
(Date:2/28/2017)... 2017  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical ... of autoimmune diseases, asthma and allergic diseases and ... quarter and full year ended December 31, 2016 ... business and clinical highlights. "During 2016, ... pipeline by starting five clinical trials across our ...
(Date:2/28/2017)... ... February 28, 2017 , ... The ... well as to their processing and transport properties. With the Litesizer™ 100 ... of samples. The Litesizer™ 100 gives rapid and accurate insight into particle systems, ...
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... ... trials, yet requires extensive coordination and expertise. Colpitts Clinical Trial Travel and ... 15 years of meeting this unique need within the biotechnology and pharmaceutical industries ...
Breaking Biology Technology:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
Breaking Biology News(10 mins):